Metyos is developing a semi-invasive, arm-worn patch that continuously senses ions and minerals beneath the skin to monitor biomarkers linked to chronic kidney disease and hyperkalemia. The device sends data via Bluetooth to a smartphone app and relays encrypted user data to Metyos’ secure cloud server for clinicians to remotely track disease progression. The team — CEO Alexandre Boulanger (formerly of Wandercraft) and CTO Olga Chashchina (PhD in biomedical engineering, biosensor expertise) — began work in 2021 and has built a prototype and completed bench tests. The startup plans to run clinical trials next to evaluate and refine the technology and is targeting regulatory approval by the end of 2025. Metyos aims for its biowearable to be prescribed as part of remote treatment management, starting with end-stage patients with hyperkalemia and extending to earlier-stage CKD patients. It is focusing on markets in Europe (especially France) and the U.S., where remote patient monitoring reimbursements exist or are being developed.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2024